Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients

Recently, an increase in the incidence of severe forms of prostate cancer, in particular castration-resistant prostate cancer (CRPC) has been noticed. Treatment of CRPC patients is associated with increasing expenses and thus impacts the healthcare budgets at various levels. The aim was to study the pharmacoeconomic aspects of using enzalutamide, cabazitaxel and abiraterone for the second-line therapy of CRPC (after treatment with docetaxel) in the Russian Federation. Materials and Methods. A cost effectiveness analysis of patient management was conducted for each of the three drugs. The direct costs included the costs of visiting the doctor, the diagnostic tests and procedures, the best supportive therapy with other drugs in accordance with the standards, the treatment of adverse events, the end-of-life palliative therapy in hospital, and the costs of prescribing one of the three drugs in question. Results. The expenses for diagnosing, maintaining the treatment regimen, consulting, monitoring and nurse caring in patients with CRPC were 15-20% lower with enzalutamide compared to abiraterone and two-fold lower than that with cabazitaxel. The general assessment of direct costs without the cost of the above drugs showed that the use of enzalutamide was 10% less expensive than abiraterone and 35% less expensive than cabazitaxel. The pharmacoeconomic advantages of enzalutamide over the two other agents are supported by the «decision tree» model and by the cost/effectiveness ratio. Conclusion. The use of enzalutamide is associated with lower direct costs of care, treatment, diagnostic and supportive procedures as compared with abiraterone and cabazitaxel. 

1. Ellis L., Lafeuille M., Gozalo L., Pilon D. et al. Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer. American Health & Drug Benefits. 2015; 8 (4): 185-195.

2. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359e86.

3. Yoo S., Choi S., You D., Kim Ch. New drugs in prostate cancer. Prostate. 2016; 4: 37-42.

4. Chissov V. I., Rusakov I. G. Eksperimental’naya i klinicheskaya urologiya (in Russian). 2011; 2 (3): 6-7.

5. Malignant neoplasms in Russia in 2014 (morbidity and mortality). Ed. AD Kaprin, VV Starinskiy, GV Petrova [Zlokachestvennye novoobrazovaniya v Rossii v 2014 godu (zabolevaemost’ i smertnost’). Pod red. A. D. Kaprina, V. V. Starinskogo, G. V. Petrovoi (in Russian)]. Moscow. 2016.

6. The state of oncological assistance to the population of Russia in 2014. Ed. AD Kaprin, VV Starinskiy, GV Petrova [Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2014 g. Pod red. A. D. Kaprina, V. V. Starinskogo, G. V. Petrovoi (in Russian)]. Moscow. 2015.

7. Rusakov I. G., Ivakhnenko O. I., Andreeva N. S., Goryainov S. V. et al. Meditsinskie tekhnologii. Otsenka i vybor (in Russian). 2012; 2: 46-56.

8. Apolikhin O. I., Sivkov A. V., Beshliev D. A. et al. Eksperimental’naya i klinicheskaya urologiya (in Russian). 2010; 1: 4-12.

9. Son I. M., Gazheva A. V., Krekina E. A. Menedzher zdravookhraneniya (in Russian). 2015; 3: 82-95.

10. Markova A. S., Polikarpova S. B., Kamolov B. Sh., Gridneva Ya. V. et al. Onkourologiya (in Russian). 2015; 2: 77-84.

11. Kirby M., Hirst C., Crawford E. D. Characterising the castrationresistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65 (11): 1180-92.

12. Alekseev B. Ya., Nyushko K. M., Kalpinskii A. S., Kaprin A. D. Onkourologiya (in Russian). 2016; 3 (12): 87-95.

13. Matveev V. B., Babaev E. R. Onkourologiya (in Russian). 2011; 2: 78-83.

14. Alekseev B. Ya., Andriyanov A. N. Onkourologiya (in Russian). 2013; 1: 34-43.

15. Fizazi K., Scher H., Molina A., Logothetis C et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, doubleblind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13: 98392.

16. de Bono J. S., Oudard S., Ozquroglu M., Hansen S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376: 1147-54.

17. Scher H., Fizazi K., Saad F., Taplin M. et al., Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N engl j med. 2012; 367 (13): 1187-97.

18. Tran, C., Ouk, S., Clegg, N., Chen, Y. Et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324: 787-790.

19. Bahl A., Masson S., Birtle A., Chowdhury S., de Bono J. Secondline treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. Cancer treatment reviews. 2014; 40: 170-177.

20. Zhong L., Pon V., Srinivas S., Nguyen N. et al. PLoS One. Therapeutic options in docetaxel-refractory metastatic castrationresistant prostate cancer: a cost-effectiveness analysis. Journal Of Clinical Oncology. 2013; May 22; 8 (5): e64275.

21. The standard of medical care for patients with malignant neoplasm of the prostate (in the provision of specialized care). Approved. Order of the Ministry of Health and Social Development of the Russian Federation of November 20, 2006. N 775. [Standart meditsinskoi pomoshchi bol’nym so zlokachestvennym novoobrazovaniem predstatel’noi zhelezy (pri okazanii spetsializirovannoi pomoshchi). Utv. Prikazom Minzdravsotsrazvitiya RF ot 20.11.2006. N 775 (in Russian)].

22. The standard of specialized medical care for malignant neoplasms of the prostate, hormone refractory form (chemotherapy treatment). Approved. Order of the Ministry of Health of the Russian Federation of 20.07.2015. № 401 ann. [Standart spetsializirovannoi meditsinskoi pomoshchi pri zlokachestvennykh novoobrazovaniyakh predstatel’noi zhelezy, gormonrefrakternaya forma (khimioterapevticheskoe lechenie). Utv. Prikazom Minzdrava RF ot 20.07.2015. № 401 an (in Russian)].

23. British National Formulary 63, March 2012. British Medical Association and the Royal Pharmaceutical Society of Great Britain.

24. Kolbin A. S., Kurylev A. A., Pavlysh A. V. Kachestvennaya klinicheskaya praktika (in Russian). 2015; 1: 18-31.

25. Kolbin A. S., Kurylev A. A., Prasolov A. V., Pavlysh A. V. Kachestvennaya klinicheskaya praktika (in Russian). 2013; 1: 2-14.

26. Web site of the NUZ “The Department of Clinical Hospital at the Kirov Station” JSC RJ URL: http://www.obskirov.ru/price. Accessed: 06.01.2017.

27. Medcompass Internet portal». URL: https://www.medkompas.ru/procedure/scintigrafiya-kostey/ (in Russian). Accessed: 06.01.2017.

28. Internet-portal «Aptekamoss». URL: www.aptekamos.ru (in Russian). Accessed: 06.01.2017.

29. Russian Pharmaceutical Internet Portal “Pharmindex”. URL: www.pharmindex.ru. (in Russian). Accessed: 06.01.2017.

30. Course of economic theory. Ed. M. N. Chepurina, E. A. Kiseleva [Kurs ekonomicheskoi teorii. Pod red. M. N. Chepurinoi, E. A. Kiselevoi (in Russian)]. Kirov. 2004.

31. Auchus R., Yu M., Nguyen S., Mundle S. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. The Oncologist. 2014; 19: 1231-1240.